A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

NCT00664248 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1414

Last updated 2008-04-22

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

IDP-110

Topical application for 12 weeks

DRUG

Clindamycin

Topical application for 12 weeks

DRUG

Benzoyl peroxide

Topical application for 12 weeks

DRUG

Vehicle

Topical application for 12 weeks

Sponsors & Collaborators

  • Dow Pharmaceutical Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-08-31

Countries

  • United States
  • Belize
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664248 on ClinicalTrials.gov